Week in Review: Novartis Opens $1 Billion Shanghai R&D Center

Novartis opened a $1 billion Shanghai R&D center that will focus on diseases prevalent in China and Asia; Guangzhou Link Health in-licensed greater China rights to a cancer drug from Germany's 4SC AG in an $85 million deal; AccuraGen Holdings, a US-China cancer diagnostics company, closed a $40 million Series B financing; Sipai Wangluo of Beijing raised "tens of millions" of dollars in a Series B round to develop oncology big data for clinical use; China is the top biopharma cluster in Asia, according Genetic Engineering & Biotechnology News; China's National Development and Reform Commission announced an investigation into drug and medical device pricing among domestic and foreign firms; WuXi Biologics and Sartorius Stedim Biotech of France opened a Shanghai joint lab for process optimization of biologic drug candidates; and Lee's Pharm of Hong Kong and US-based RegeneRx used new China regulations to accelerate development of a dry eye drug. More details.... Stock Symbols: (NYSE: NVS) (FSE: VSC) (EPA: DIM) (HK: 0950) (OTCQB: RGRX) Share this with colleagues: // //